Phosphorylation of Hsp20 Promotes Fibrotic Remodeling and Heart Failure

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Fibrosis Research

Background:

• Elevated cardiomyocyte phosphorylated heat shock protein 20 (Hsp20) mirrors human heart failure.
• This condition is linked to early fibrotic remodeling and impaired left ventricular function.
• Progression leads to heart failure and premature mortality.

Purpose of the Study:

• To investigate the mechanisms linking phosphorylated Hsp20 to cardiac dysfunction and fibrosis.
• To evaluate the therapeutic potential of targeting interleukin-6 (IL-6) signaling in this model.

Main Methods:

• Utilized a mouse model with cardiomyocyte-specific increases in phosphorylated Hsp20 (S16D-Hsp20).
• Investigated nuclear translocation of phosphorylated Hsp20 and IL-6 upregulation.
• Administered a rat anti-mouse IL-6 receptor monoclonal antibody (MR16-1) to S16D-Hsp20 mice.
• Assessed interstitial fibrosis and cardiac function via established methodologies.

Main Results:

• Phosphorylated Hsp20 translocation to the nucleus and subsequent IL-6 upregulation were observed.
• IL-6 activated cardiac fibroblasts through STAT3 signaling.
• MR16-1 treatment significantly attenuated interstitial fibrosis.
• Cardiac function was preserved in treated S16D-Hsp20 mice.

Conclusions:

• Phosphorylated Hsp20 drives cardiac fibrosis and dysfunction via IL-6/STAT3 signaling.
• Targeting the IL-6 receptor with MR16-1 offers a potential therapeutic strategy.
• Phosphorylated Hsp20 represents a promising therapeutic target for heart failure treatment.